- Home
- / MABWELL
MABWELL
Stock Price
¥24
2024-10-29
Market Capitalization
¥9.1 B
2024-10-29
Revenue
¥646.6 M
FY, 2025
MABWELL Summary
Company Summary
- Overview
- MABWELL is a biopharmaceutical company that manufactures drugs. Its products include vaccines, monoclonal antibodies, and acting cytokine drugs. The company offers commercialization, clinical research, R&D, and production services.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- CN | view all locations
- Website
- https://www.mabwell.com
- Cybersecurity rating
Table of Contents
LocationsView all
1 location detected
Shang Hai Shi HQ
China
Li Bing Lu, Pu Dong Xin Qu
MABWELL Financials
Summary Financials
- Revenue (Q1, 2026)
- ¥125.8M
- Gross profit (Q1, 2026)
- ¥95.3M
- Net income (Q1, 2026)
- (¥243.0M)
- Cash (Q1, 2026)
- ¥1.5B
- EBIT (Q1, 2026)
- (¥206.9M)
- Enterprise value
- $10.9B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026